No Data
Repligen Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Initiates Repligen(RGEN.US) With Buy Rating, Announces Target Price $180
Repligen Price Target Lowered to $180 From $240 at H.C. Wainwright
RBC Capital Keeps Their Buy Rating on Repligen (RGEN)
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
Repligen Announced The Commercial Launch Of Its CTech SoloVPE PLUS System For At-line Ultraviolet-visible Concentration Measurement In Complex Biological Production Workflows, From Process Development Scale Through CGMP Manufacturing
Repligen Corporation's (NASDAQ:RGEN) Popularity With Investors Is Clear
